Syndromic insulin resistance: Models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages 763-771

  Gorden, Phillip ^a   Zadeh, Elika Safar ^a   Cochran, Elaine ^a   Brown, Rebecca J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN RECEPTOR ANTIBODY; LEPTIN; LEVOTHYROXINE; METFORMIN; METRELEPTIN; ORAL ANTIDIABETIC AGENT; RITUXIMAB; ROSIGLITAZONE; STEROID;

ACANTHOSIS NIGRICANS; ADD ON THERAPY; ADOLESCENT; ADULT; CASE REPORT; CHILD; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG PULSE THERAPY; FAMILIAL PARTIAL LIPODYSTROPHY; FEMALE; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GROWTH RETARDATION; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LEPTIN DEFICIENCY; LIPODYSTROPHY; MALE; MANDIBULOACRAL DYSPLASIA ASSOCIATED LIPODYSTROPHY; METABOLIC SYNDROME X; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PHENOTYPE; PLASMAPHERESIS; PRACTICE GUIDELINE; PRESCHOOL CHILD; PROFESSIONAL STANDARD; REVIEW; SIBLING; SYNDROMIC INSULIN RESISTANCE; THYROID CANCER; TYPE B INSULIN RESISTANCE; XANTHOMA;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; YOUNG ADULT;

EID: 84867374953     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12139.RA     Document Type: Review

References (63)

1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
2. Allison DB, Zannolli R, Narayan KM. The direct health care costs of obesity in the United States. Am J Public Health. 1999;89:1194-1199.
3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583-2589.
4. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012;82:1-8.
5. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general informa-Tion on diabetes and prediabetes in the United States, 2011. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
6. Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006;160:523-528.
7. Reaven GM. Banting lecture 1988. Role of insulin resis-Tance in human disease. Diabetes. 1998;37:1595-1607.
8. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internationl Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
9. The effect of intensive treatment of diabetes on the devel-opment and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-986.
10. Nathan DM, Cleary PA, Backlund JY, et al Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treat-ment and cardiovascular disease in patients with type 1 dia-betes. N Engl J Med. 2005;353:2643-2653.
11. Gorden P, Musso C. The impact of evidence-based medi-cine on diabetes therapy. Curr Diab Rep. 2005;5:157-159.
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabe-Tes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [Erratum in Lancet. 1998;352:158]. Lancet. 1998; 352:854-865.
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
14. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue [Erratum in: Nature. 1995;374: 479]. Nature. 1994;372:425-432.
15. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295.
16. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA. 1999;282:1568-1575.
17. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879-884.
18. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congeni-Tal leptin deficiency. J Clin Invest. 2002;110:1093-1103.
19. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234.
20. Garg A. Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313-3325.
21. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabe-Tes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-76.
22. Ebihara K, Ogawa Y, Masuzaki H, et al. Transgenic overexpression of leptin rescues insulin resistance and dia-betes in a mouse model of lipoatrophic diabetes. Diabetes. 2001;50:1440-1448.
23. Moran SA, Patten N, Young JR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53:513-519.
24. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-1350.
25. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-Term efficacy of leptin replace-ment in patients with generalized lipodystrophy. Diabetes. 2005;54:1994-2002.
26. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-Term efficacy of leptin replacement in patients with Dunnigan-Type familial partial lipodystrophy. Metabolism. 2007;56:508-516.
27. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodys-Trophy. Diabetologia. 2010;53:27-35.
28. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement ther-Apy for lipodystrophy. N Engl J Med. 2002;346:570-578.
29. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345-1350.
30. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005;41:753-760.
31. Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogen-ism in lipodystrophic women with polycystic ovarian syn-drome. J Clin Endocrinol Metab. 2012;97:563-567.
32. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351:987-997.
33. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-Term metreleptin treatment in patients with lipodystro-phy. Endocr Pract. 2011;17:922-932.
34. Gorden P, Lupsa BC, Chong AY, Lungu AO. Is there a human model for the 'metabolic syndrome' with a defined aetiology? Diabetologia. 2010;53:1534-1536.
35. Bar RS, Gorden P, Roth J, Kahn CR, De Meyts P. Fluctuations in the affinity and concentration of insu-lin receptors on circulating monocytes of obese patients: Effects of starvation, refeeding, and dieting. J Clin Invest. 1976;58:1123-1135.
36. Samuel VT, Shulman GI. Mechanisms for insulin resis-Tance: Common threads and missing links. Cell. 2012;148: 852-871.
37. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-543.
38. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010;11:11-22.
39. Schwartz MW, Baskin DG, Bukowski TR, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes. 1996;45:531-535.
40. Hidaka S, Yoshimatsu H, Kondou S, et al. Chronic cen-Tral leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced dia-betic rats. FASEB J. 2002;16:509-518.
41. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoanti-bodies to the insulin receptor (type B insulin resistance): A 28-year perspective. Medicine (Baltimore). 2002;81: 87-100.
42. Coll AP, Morganstein D, Jayne D, Soos MA, O'Rahilly S, Burke J. Successful treatment of type B insulin resis-Tance in a patient with otherwise quiescent systemic lupus erythematosus. Diabet Med. 2005;22:814-815.
43. Malek R, Chong AY, Lupsa BC, et al. Treatment of type B insulin resistance: A novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab. 2010; 95:3641-3647.
44. Gorden P, Collier E, Roach P. Autoimmune mechanisms of insulin resistance and hypoglycemia. In: Moley DE, ed. Insulin Resistance. London, UK: John Wiley, 1993: 123-124.
45. Sluss PM, Schneyer AL. Low molecular weight follicle-stimulating hormone receptor binding inhibitor in sera from premature ovarian failure patients. J Clin Endocrinol Metab. 1992;74:1242-1246.
46. Peter JC, Bekel A, Lecourt AC, et al. Anti-melanocortin-4 receptor autoantibodies in obesity. J Clin Endocrinol Metab. 2009;94:793-800.
47. Juppner H, Bialasiewicz AA, Hesch RD. Autoantibodies to parathyroid hormone receptor. Lancet. 1978;2:1222-1224.
48. Kifor O, McElduff A, LeBoff MS, et al. Activating anti-bodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab. 2004;89:548-556.
49. Taylor SI, Barbetti F, Accili D, Roth J, Gorden P. Syndromes of autoimmunity and hypoglycemia. Autoantibodies directed against insulin and its receptor. Endocrinol Metab Clin North Am. 1989;18:123-143.
50. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine (Baltimore). 2009;88:141-153.
51. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab. 2004;89,1548-1554.
52. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): A 30-year prospective. Medicine (Baltimore) 2004;83:209-222.
53. Skarulis MC, Celi FS, Mueller E, et al. Thyroid hormone induced brown adipose tissue and amelioration of dia-betes in a patient with extreme insulin resistance. J Clin Endocrinol Metab. 2010;95:256-262.
54. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contrib-utes to thermogenic activation of neonatal brown fat. Cell Metab. 2010;11:206-212.
55. Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1a and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271-281.
56. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
57. Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018-6027.
58. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-Alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468.
59. Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogen-ism in lipodystrophic women with polycystic ovarian syn-drome. J Clin Endocrinol Metab. 2012;97:563-567.
60. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resis-Tance. Endocr Rev. 2011;32:498-514.
61. Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibod-ies. Diabetes. 2007;56:1712-1717.
62. Semple RK, Soos MA, Luan J, et al. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab. 2006;91:3219-3223.
63. Sleigh A, Raymond-Barker P, Thackray K, et al. Mitochondrial dysfunction in patients with primary congen-ital insulin resistance. J Clin Invest. 2011;121:2457-2461.